Search Results

You are looking at 181 - 190 of 2,860 items for :

  • Refine by Access: All x
Clear All
Full access

Joining Together to Improve Outcomes: Integrating Specialty Palliative Care Into the Care of Patients With Cancer

Maxwell T. Vergo and Amelia M. Cullinan

process, and therefore involvement at least 3 to 6 months before cessation of chemotherapy would be ideal to affect outcomes. Figure 1. Palliative care integrated into the continuum of care. Applying these criteria to the present case, Mr

Full access

BBCIC Research Network Analysis of First-Cycle Prophylactic G-CSF Use in Patients Treated With High–Neutropenia Risk Chemotherapy

Pamala A. Pawloski, Cara L. McDermott, James H. Marshall, Vanita Pindolia, Catherine M. Lockhart, Catherine A. Panozzo, Jeffrey S. Brown, and Bernadette Eichelberger

use in real-world settings are maturing, and critical pharmacovigilance of these products depends on the understanding of their use and clinical impact. 30 , 31 Similar clinical and safety outcomes of the G-CSF biosimilars compared with their

Full access

HSR23-095: Outcomes of Patients With Pancreatic Cancer Undergoing Duodenal Stent Placement: A Population-Based Study

Neethi Dasu, Kirti Dasu, Jason John, Yaser Khalid, Lucy Joo, Brian Blair, and C. Jonathan Foster

, duodenal stents are used to treat patients who are considered high-risk surgical candidates. We aimed to study the survival and clinical outcomes after endoscopic duodenal stent placement for patients with pancreatic cancer in comparison to patients who do

Full access

CLO22-034: Subtotal Glossectomy. Functional Outcomes After Compartmental Tongue Resection and Reconstruction With Pectoralis Major Myocutaneous Flap

Haider Abdulraheem Alalawy

tongue surgery approach. The surgical defect was reconstructed by PMMF. The functional outcome was measured using the University of Washington Quality of Life Questionnaire (UW-QOL). Oncologic and functional outcome evaluated during the follow up period

Full access

CLO23-048: Disparities in Outcomes of Chemotherapy-Related Febrile Neutropenia Patients: A Nationwide Study of Hospitalizations

Akhil Jain, Sohiel Deshpande, Krishna Desai, Sabah Iqbal, Aisha Sultan, Monika Garg, Bohdan Baralo, and Rajesh Thirumaran

analyze the regional disparities in the outcomes of hospitalized FN patients. Methods: Using NIS 2016-19 datasets, we identified chemotherapy related FN hospitalizations (ICD-10-CM codes) and analyzed (weighted) for differences in demographics, admitting

Full access

Safety and Efficacy of FOLFOX Followed by Cetuximab for Metastatic Colorectal Cancer With Severe Liver Dysfunction

Raymond Elsoueidi, Jessica Craig, Hesham Mourad, and Elie M. Richa

Infusional 5-FU monotherapy has been used in patients with severe liver dysfunction, but the clinical outcomes have been disappointing. 8 FOLFOX and FOLFIRI have resulted in superior responses and survival rates compared with 5-FU alone. 9 However, the

Full access

Salvage or Adjuvant Radiation Therapy: Counseling Patients on the Benefits

Matthew E. Nielsen, Bruce J. Trock, and Patrick C. Walsh

within 2 years of biochemical recurrence. Additionally, consistent with other studies examining biochemical outcome after salvage RT, the survival benefit in this study cohort was seen only among men whose PSA became undetectable after salvage RT. 9

Full access

Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair–Deficient Colorectal Cancer

Bin-Yi Xiao, Xuan Zhang, Tai-Yuan Cao, Dan-Dan Li, Wu Jiang, Ling-Heng Kong, Jing-Hua Tang, Kai Han, Chen-Zhi Zhang, Wei-Jian Mei, Jian Xiao, Zhi-Zhong Pan, Yun-Feng Li, Xiao-Shi Zhang, and Pei-Rong Ding

unresectable, and 3 refused surgery for unspecified reasons. Outcomes of Patients With Locally Advanced (cT4a/4b) Disease A total of 48 patients had locally advanced disease, with CR and PR observed in 4 (8.3%) and 37 (77.1%) of them, respectively; the

Full access

QIM22-191: Expansion of Tobacco Cessation Treatment Within the Stanford Cancer Institute: 6-Month and 24-Month Outcomes

Amy Chieng, Maura Chandler, Cindy Tran, Brittany Pike, Alexandra Liu, LittleDove Faith Rey, Lauren Haruno, Annemarie Jagielo, Amy Pirkl, and Judith J Prochaska

cessation treatment into cancer care. The funding, technical, and peer support from the C3I collaboration was instrumental in extending Stanford’s tobacco treatment service into 20+ clinics across 3 cancer centers. Aim : To report on patient outcomes at 6

Full access

HSR24-130: Real-World Outcomes in Patients With Burkitt Lymphoma in a Safety-Net Health System

Maria Lee, Jun Y. Jiang, Chijioke Nze, Danielle Guffey, Rockbum Kim, Abiodun O. Oluyomi, Omar Rosales, Raka Bandyo, Courtney N. Miller-Chism, Mark M. Udden, Martha P. Mims, Hilary Ma, Gustavo A. Rivero, Akiva Diamond, Purnima S. Teegavarapu, Christopher R. Flowers, Ang Li, and Sara Taveras Alam

Background: Burkitt lymphoma (BL) outcomes have improved in the last decade. However, studies examining patients who are uninsured or have socioeconomic barriers to care are limited. We conducted a retrospective cohort analysis of BL patients